Enrica Morra

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

Francesco Passamonti, Elisa Rumi, Ester Pungolino et al. · The American Journal of Medicine · 2004 · 448 citations

Thrombopoiesis, Thrombosis, Polycythemia Vera +9

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7

Consensus conference on the management of tumor lysis syndrome

Patrizia Tosi, Giovanni Barosi, Carlo Lazzaro et al. · Haematologica · 2008 · 134 citations · Full text

Massive Cellular Lysis, Urology, Surgical Oncology +13

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13